Urology

Edited by: Steve Bunk W.J. Catalona, D.S. Smith, R.L. Wolfert, T.J. Wang, H.G. Rittenhouse, T.L. Ratliff, R.B. Nadler, "Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening," JAMA-Journal of the American Medical Association, 274:1214-20, 1995. (Cited in 89 papers through August 1997) LESS WORK: Measuring free PSA in serum in screening for prostate cancer will necessitate fewer biopsies than will measuring total PSA, says urologis

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Edited by: Steve Bunk
W.J. Catalona, D.S. Smith, R.L. Wolfert, T.J. Wang, H.G. Rittenhouse, T.L. Ratliff, R.B. Nadler, "Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening," JAMA-Journal of the American Medical Association, 274:1214-20, 1995. (Cited in 89 papers through August 1997)


LESS WORK: Measuring free PSA in serum in screening for prostate cancer will necessitate fewer biopsies than will measuring total PSA, says urologist William Catalona.
Comments by William J. Catalona, Department of Surgery, Washington University School of Medicine, St. Louis

The main problem with the current method of broad-based prostate cancer screenings for older men, say critics in the medical community, is that too many false-positive readings result. This high rate prompts doctors to routinely order biopsies, which often come up negative. Biopsies are costly and uncomfortable, and carry the potential for infection, notes William J. Catalona, a urologist in the department ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Steve Bunk

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours